<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Diabetic foot problems. Inpatient management of diabetic foot problems.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Centre for Clinical Practice. Diabetic foot problems. Inpatient management of diabetic foot problems. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 31 p.&amp;nbsp;(Clinical guideline; no. 119).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. &lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Foot pressure off loading/supportive device, any type, each "/><FieldValue Value="ICD9CM: Arthropathy associated with neurological disorders  (713.5); Chronic osteomyelitis, ankle and foot  (730.17); Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled  (250.61); Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled  (250.60); Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled  (250.71); Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled  (250.70); Ulcer of lower limb, unspecified  (707.10); Unspecified infection of bone, lower leg  (730.96); Unspecified osteomyelitis, site unspecified  (730.20)"/><FieldValue Value="MSH: Anti-Bacterial Agents ; Arthropathy, Neurogenic ; Bandages ; Culture Techniques ; Debridement ; Diabetic Foot ; Foot Deformities ; Foot Ulcer ; Inflammation ; Inpatients ; Ischemia ; Magnetic Resonance Imaging ; Microbiological Techniques ; Negative-Pressure Wound Therapy ; Osteomyelitis ; Patient Care Team ; Patient Education as Topic ; Radiography ; Radionuclide Imaging ; Referral and Consultation ; Social Support "/><FieldValue Value="MTH: Anti-Bacterial Agents ; Bandage ; Culture Techniques ; Debridement ; Diabetic Foot ; Diabetic foot ulcer ; Foot Deformities ; Inflammation ; inpatient ; Ischemia ; Magnetic Resonance Imaging ; Neurogenic arthropathy ; Osteomyelitis ; Osteomyelitis of lower leg ; Patient education (procedure) ; Radiographic imaging procedure ; Radiography of foot ; Radionuclide Imaging ; Social support ; Sterile coverings ; White blood cell scan "/><FieldValue Value="PDQ: magnetic resonance imaging ; radionuclide imaging "/><FieldValue Value="SNOMEDCT_US: Antibacterial agent  (346325008); Antibacterial agent  (419241000); Arthropathy associated with a neurological disorder  (359554008); Arthropathy associated with a neurological disorder  (67536000); Bandage  (63995005); Chronic osteomyelitis of the ankle and/or foot  (268019002); Debridement  (129317004); Debridement  (36777000); Debridement of foot ulcer  (312733004); Deformity of foot  (229844004); Diabetic foot  (280137006); Diabetic foot ulcer  (371087003); Diabetic neuropathic arthropathy  (201724008); Dressings  (333453004); Examination of foot  (284384005); Infection of foot  (299990002); Inflammation  (23583003); Inflammation  (257552002); Inpatient  (416800000); Ischemia  (52674009); Ischemia of feet  (300917007); Ischemic ulcer diabetic foot  (201250006); Lower limb ischemia  (233961000); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Neuropathic diabetic ulcer - foot  (201251005); Nuclear medicine imaging procedure  (373205008); Osteomyelitis  (60168000); Osteomyelitis of lower leg  (21120002); Patient education  (311401005); Radiographic imaging procedure  (363680008); Radiography of foot  (52221007); Ulcer of foot  (95345008)"/><FieldValue Value="SPN: DRESSING ; SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING "/><FieldValue Value="UMD: Bandages  (10-274); Dressings  (11-315); Radiographic Systems  (18-429); Scanning Systems, Magnetic Resonance Imaging  (16-260)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Diabetic foot problems including neuropathy, peripheral arterial disease, ischaemia, ulceration, gangrene, inflammation and/or infection, deformity, osteomyelitis, and Charcot arthropathy&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Infectious Diseases" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nursing" /><FieldValue Value="Orthopedic Surgery" /><FieldValue Value="Physical Medicine and Rehabilitation" /><FieldValue Value="Podiatry" /><FieldValue Value="Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Hospitals" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Podiatrists" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To offer best practice advice on the hospital-based care of people with diabetic foot problems&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults (18 years and older) with or at a particular high risk (high risk as defined in National Institute for Health and Clinical Excellence [NICE] clinical guideline 10) of diabetic foot problems admitted to hospital&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Children (younger than 18 years) will not be covered.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Use of a multidisciplinary foot team for management of diabetic foot problems &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duties of the multidisciplinary foot team in relation to assessment, review, and treatment of diabetes and diabetic foot problem &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Offering patients information and support about their diagnosis and treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referring the patient to the multidisciplinary foot care team within 24 hours of the initial examination of the patient's feet &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initial examination and assessment for neuropathy, ischaemia, ulceration, inflammation and/or infection, deformity, Charcot arthropathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Investigation of suspected diabetic foot infection, including microbial examination of soft tissue sample, x-ray, magnetic resonance imaging (MRI), or white blood cell scanning &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of oral or intravenous antibiotics for foot infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of debridement, wound dressings, and off-loading for foot ulcers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Negative pressure wound therapy for foot ulcers (not recommended routinely) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment for limb ischemia and referral to specialist &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following interventions were considered but specifically not recommended: technetium-99 conjugated with methylene diphosphonate [99mTc-MDP]-labelled scintigraphy, 99mTc-hexamethyl propylene amine oxime [HMPAO]-labelled scintigraphy, antigranulocyte Fab' fragment antibody scintigraphy, and 99mTc-labelled monoclonal antigranulocyte antibody scintigraphy for assessment of foot infection; dermal or skin substitutes, electrical stimulation therapy, autologous platelet-rich plasma gel, regenerative wound matrices and deltaparin, growth factors (granulocyte colony-stimulating factor [G-CSF], platelet-derived growth factor [PDGF], epidermal growth factor [EGF] and transforming growth factor beta [TGF-&amp;beta;]), hyperbaric oxygen therapy for treatment of foot ulcers.&lt;/p&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Rates and extent of amputation (major or minor) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Length of hospital stay &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rates of hospital readmission &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health related quality of life (QoL) of people with diabetic foot problems (Ideally this will include data from validated generic instruments such as the EQ-5D that are able to provide a single index value of health status [on a scale of 0 to 1]. Generic health survey questionnaire data, such as from the Short Form 36, may also be appropriate) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resource use and costs &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at National Institute for Health and Clinical Excellence (NICE).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Search Strategies&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Scoping Searches&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Scoping searches were undertaken on a number of websites and databases (see Appendix C of the full version of the original guideline document for a complete list) in November 2009 to provide information for scope development and project planning. Browsing or simple search strategies were employed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Main Searches&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Sources Searched for the Guideline&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Allied and Complementary Medicine Database &amp;ndash; AMED (HDAS/Search 2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;British Nursing Index &amp;ndash; BNI (HDAS/Search 2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health Business Elite (HDAS/Search 2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cochrane Database of Systematic Reviews &amp;ndash; CDSR (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cochrane Central Register of Controlled Trials &amp;ndash; CENTRAL (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Database of Abstracts of Reviews of Effects &amp;ndash; DARE (Wiley and CRD website) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health Technology Assessment Database &amp;ndash; HTA (Wiley and CRD website) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cumulative Index to Nursing and Allied Health Literature - CINAHL (HDAS/Search 2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EMBASE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health Management Information Consortium - HMIC (HDAS/Search 2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE In-Process (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PsycINFO (Ovid) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Identification of Evidence on Diabetic Foot Problems&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The searches were conducted between the 24th-25th of February 2010. The aim of the searches was to identify evidence on diabetic foot problems.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MEDLINE search strategy is presented below. It was translated for use in all of the other databases.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Database: Ovid MEDLINE(R) &amp;lt;1950 to February Week 2 2010&amp;gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;1 Diabetic Foot/&lt;/p&gt;&#xD;&#xA;&lt;p&gt;2 (diabet$ and (foot$ or feet$)).tw.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;3 1 or 2&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Economic Evaluations and Quality of Life Data&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Sources Searched to Identify Economic Evaluations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;NHS Economic Evaluation Database &amp;ndash; NHS EED (Wiley and CRD website) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health Economic Evaluations Database &amp;ndash; HEED (Wiley) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EMBASE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE (Ovid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE In-Process (Ovid) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Identification of Health Economics and Quality of Life Studies on Diabetic Foot Problems&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The searches were undertaken between 25th February-3rd March 2010. The MEDLINE search strategy that was used is presented in the section above (Identification of Evidence on Diabetic Foot Problems). Search filters to retrieve economic evaluations and quality of life papers were appended to the search strategies to identify relevant evidence. The MEDLINE economic evaluations and quality of life search filters were translated for use in the MEDLINE In-Process and EMBASE databases.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Further details of the search strategies and filter used for the systematic review of economic evaluations and quality of life are provided in Appendix C of the full version of the original guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The literature search retrieved 9817 studies. Of these, 5 studies were included for review question 1, 35 studies were included for review question 2, 14 studies were included for review question 3, 13 studies were included for review question 4, 37 studies were included for review question 5, and 0 were included for review question 6. See Appendix D of the full version of the original guideline document for a detailed breakdown of included and excluded studies for each question.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus (Committee)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Meta-Analysis" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at National Institute for Health and Clinical Excellence (NICE). 'Diabetic foot problems. Inpatient management of diabetic foot problems' is a NICE short clinical guideline. For a full explanation of how this type of guideline is developed, see 'The guidelines manual' (2009) (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline is structured into six sections based on the review questions. Evidence in each section is presented in the summary of GRADE (Grading of Recommendations Assessment, Development and Evaluation) profiles and relevant evidence statements (which are cross-referred to individual summaries of GRADE profiles). Additional information, such as the full GRADE evidence profiles and outputs of different analyses, such as meta-analyses, summaries of receiver&amp;ndash;operator&amp;ndash;characteristics (ROC) and others, are available in the appendices. References of all included studies are also available in Appendix D (see the full version of the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Health Economic Modelling&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Examination of the existing literature and the quality of the evidence available suggested that an economic analysis would not be possible for the majority of this guideline. However, the Guideline Development Group (GDG) considered that analyses would be required in two areas to help inform decision making. Firstly, does magnetic resonance imaging (MRI) for the diagnosis of osteomyelitis represent a cost-effective use of resources? Secondly, are hyperbaric oxygen therapy (HBOT) and negative pressure wound therapy cost-effective treatments for diabetic foot problems? These areas are considered in Sections 3.2.4 and 3.5.4 (see the full version of the original guideline document). Given the low quality of the evidence these analyses should be considered as exploratory. No other areas were considered for health economic modelling.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at the National Institute for Health and Clinical Excellence (NICE).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Forming and Running the Short Clinical Guideline Development Group (GDG)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each short clinical guideline is developed by a unique GDG consisting of 10&amp;ndash;12 members, supported by the Short Clinical Guidelines Team. Each GDG has a Chair, healthcare professional members and a minimum of two patient and carer members. Co-opted expert advisers are recruited, as appropriate. A Clinical Adviser, who has specific content expertise and additional responsibilities, may also be appointed depending on the topic. Recruitment of the GDG Chair and members is carried out in accordance with NICE's policy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The GDG makes its decisions using the best available evidence presented to it at GDG meetings by the Short Clinical Guidelines Team. The use of formal consensus methods within the GDG will be considered on a case-by-case basis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Developing Review Questions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A short clinical guideline has a narrow scope and covers only part of a care pathway. It addresses a maximum of three subject areas covering clinical management. This will result in a small number of key clinical issues. These are broken down into a defined number of review questions &amp;mdash; usually one or two per clinical management area. The exact number will be dictated by the size of the short clinical guideline remit and the amount of development time available.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Creating Guideline Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Explicit methods of linking the evidence to recommendations are used for short clinical guidelines if the topic is suitable. This involves using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Research recommendations are formulated for short clinical guidelines. Their number is dependent on the size of the short clinical guideline remit and the amount of development time available.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Writing the Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There are usually three versions of short clinical guidelines:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The full guideline &amp;ndash; all the recommendations, details of how they were developed and summaries of the evidence they are based on. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The quick reference guide &amp;ndash; a summary of the recommendations for healthcare professionals. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;'Understanding NICE guidance' &amp;ndash; a summary for patients and carers. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The full guideline is written by the Short Clinical Guidelines Team, following the principles in chapters 9 and 10 of 'The guidelines manual' (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Cost-Effectiveness Analyses of Magnetic Resonance Imaging (MRI)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;These analyses indicate that MRIs are likely to be cost effective if delayed treatment for osteomyelitis is associated with worse outcomes and increased amputation rates. The Guideline Development Group (GDG) considered that, while no high-quality evidence was available to demonstrate this, it was a reasonable assumption given current clinical knowledge. Therefore, MRI appears to be a cost-effective use of resources. Please see Section 3.2.4 and Appendix J of the full version of the original guideline for more details.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cost-Effectiveness Analyses of Negative Pressure Wound Therapy (NPWT) and Hyperbaric Oxygen Therapy (HBOT)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Results indicate that NPWT is associated with incremental cost-effectiveness ratios (ICERs) above what is normally considered cost effective, and are unlikely to be cost effective. HBOT is associated with ICERs between &amp;pound;20,000 per quality-adjusted life-year (QALY) and &amp;pound;30,000 per QALY and therefore, consideration must be given to issues of the uncertainty in the analysis. The probabilistic analysis indicates that HBOT has just over 50% probability of being cost effective at &amp;pound;30,000 per QALY threshold.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Sensitivity analysis indicated that it would be possible for the treatments to be considered cost effective if the difference in utility between healed and amputation was increased, the cost of amputations was higher and the costs of the interventions were reduced. The GDG noted the absence of long-term benefits in the analysis and considered that their inclusion would reduce the ICERs. However, the GDG considered that, given the uncertainty around the clinical estimates, the cost effectiveness of these therapies had not been demonstrated. Please see Section 3.5.4 and Appendix J of the full version of original guideline for more details.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was validated through two consultations.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The first draft of the guideline (the full guideline, National Institute for Health and Clinical Excellence [NICE] guideline, and Quick Reference Guide) were consulted with stakeholders and comments were considered by the Guideline Development Group (GDG) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The final consultation draft of the full guideline, the NICE guideline and the Information for the Public were submitted to stakeholders for final comments. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The final draft was submitted to the Guideline Review Panel for review prior to publication.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline was developed by the Centre for Clinical Practice at National Institute for Health and Clinical Excellence (NICE). See the &quot;Availability of Companion Documents&quot; field for the full version of this guidance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Multidisciplinary Foot Care Team&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each hospital should have a care pathway for patients with diabetic foot problems who require inpatient care (the term 'diabetic foot problems requiring inpatient care' refers to people with diabetes who have i) an ulcer, blister or break in the skin of the foot; ii) inflammation or swelling of any part of the foot, or any sign of infection; iii) unexplained pain in the foot; iv) fracture or dislocation in the foot with no preceding history of significant trauma; v) gangrene of all or part of the foot. Diabetes UK [2009]: 'Putting feet first: commissioning specialist services for the management and prevention of diabetic foot disease in hospitals'.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A multidisciplinary foot care team should manage the care pathway of patients with diabetic foot problems who require inpatient care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The multidisciplinary foot care team should consist of healthcare professionals with the specialist skills and competencies necessary to deliver inpatient care for patients with diabetic foot problems.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The multidisciplinary foot care team should normally include a diabetologist, a surgeon with the relevant expertise in managing diabetic foot problems, a diabetes nurse specialist, a podiatrist and a tissue viability nurse, and the team should have access to other specialist services required to deliver the care outlined in this guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The multidisciplinary foot care team should:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assess and treat the patient's diabetes, which should include interventions to minimise the patient's risk of cardiovascular events, and any interventions for pre-existing chronic kidney disease or anaemia (see &lt;a href=&quot;http://guidance.nice.org.uk/CG73&quot; title=&quot;NICE Web site&quot;&gt;Chronic kidney disease&lt;/a&gt;, NICE clinical guideline 73 and &lt;a href=&quot;/content.aspx?id=34281&quot; title=&quot;Guideline #8661&quot;&gt;Anaemia management in people with chronic kidney disease&lt;/a&gt;, NICE clinical guideline 114) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess, review and evaluate the patient's response to initial medical, surgical and diabetes management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess the foot, and determine the need for specialist wound care, debridement, pressure off-loading and/or other surgical interventions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess the patient's pain and determine the need for treatment and access to specialist pain services. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Perform a vascular assessment to determine the need for further interventions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Review the treatment of any infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determine the need for interventions to prevent the deterioration and development of Achilles tendon contractures and other foot deformities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Perform an orthotic assessment and treat to prevent recurrent disease of the foot &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Have access to physiotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arrange discharge planning, which should include making arrangements for the patient to be assessed and their care managed in primary and/or community care, and followed up by specialist teams (see &lt;a href=&quot;http://guidance.nice.org.uk/CG10&quot; title=&quot;NICE Web site&quot;&gt;Type 2 diabetes: prevention and management of foot problems&lt;/a&gt;, NICE clinical guideline 10.) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patient Information and Support&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer patients consistent, relevant information and clear explanations that support informed decision making, and provide opportunities for them to discuss issues and ask questions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The patient should have a named contact (this may be a member of the multidisciplinary foot care team or someone with a specific role as an inpatient pathway coordinator)&amp;nbsp;to follow the inpatient care pathway and be responsible for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Offering patients information about their diagnosis and treatment, and the care and support that they can expect &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Communicating relevant clinical information, including documentation prior to discharge, within and between hospitals and to primary and/or community care &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Care: Within 24 Hours of a Patient with Diabetic Foot Problems Being Admitted to Hospital, or the Detection of Diabetic Foot Problems (if the Patient Is Already in Hospital)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A named consultant should be accountable for the overall care of the patient and for ensuring that healthcare professionals provide timely care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer the patient to the multidisciplinary foot care team within 24 hours of the initial examination of the patient's feet. Transfer the responsibility of care to a consultant member of the multidisciplinary foot care team if a diabetic foot problem is the dominant clinical factor for inpatient care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The named consultant and the healthcare professionals from the existing team remain accountable for the care of the patient unless their care is transferred to the multidisciplinary foot care team.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Examination and Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Remove the patient's shoes, socks, bandages and dressings and examine their feet for evidence of:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Neuropathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ischaemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ulceration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inflammation and/or infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Deformity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Charcot arthropathy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Document any identified new and/or existing diabetic foot problems.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consider a diagnosis of Charcot arthropathy if there is deformity, redness or warmth. Refer to an appropriate specialist to confirm the diagnosis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Examine the patient for signs and symptoms of systemic sepsis (such as fever, tachycardia, hypotension, reduced consciousness or altered cognitive state).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;X-ray the patient's affected foot (or feet) to determine the extent of the foot problem.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the patient has a diabetic foot ulcer, assess and document:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Deformity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gangrene &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ischaemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neuropathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Signs of infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The size and depth of the ulcer &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Obtain urgent advice from an appropriate specialist if any of the following are present:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Fever or any other signs or symptoms of systemic sepsis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical concern that there is a deep-seated infection (for example palpable gas) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Limb ischaemia &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Use pressure-relieving support surfaces and strategies in line with &lt;a href=&quot;http://guidance.nice.org.uk/CG29&quot; title=&quot;NICE Web site&quot;&gt;Pressure ulcers&lt;/a&gt; (NICE clinical guideline 29) to minimise the risk of pressure ulcers developing.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Investigation of Suspected Diabetic Foot Infection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If a moderate to severe soft tissue infection is suspected and a wound is present, send a soft tissue sample from the base of the debrided wound for microbiological examination. If this cannot be obtained, a superficial swab may provide useful information on the choice of antibiotic therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If osteomyelitis is suspected and initial X-ray does not confirm the presence of osteomyelitis, use magnetic resonance imaging (MRI). If MRI is contraindicated, white blood cell (WBC) scanning may be performed instead.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not exclude osteomyelitis on the basis of X-rays alone. X-rays should be used for alternative diagnoses, such as Charcot arthropathy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not exclude osteomyelitis on the basis of probe-to-bone testing.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not use the following bone scans to diagnose osteomyelitis: Technetium-99 conjugated with methylene diphosphonate (99mTc-MDP)-labelled scintigraphy, 99mTc-hexamethyl propylene amine oxime (HMPAO)-labelled scintigraphy, antigranulocyte Fab' fragment antibody scintigraphy or 99mTc-labelled monoclonal antigranulocyte antibody scintigraphy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Diabetic Foot Infection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each hospital should have antibiotic guidelines for the management of diabetic foot infections.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not delay starting antibiotic therapy for suspected osteomyelitis pending the results of the MRI scan.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Start empirical antibiotic therapy based on the severity of the infection, using the antibiotic appropriate for the clinical situation and the severity of the infection, and with the lowest acquisition cost.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For mild infections, offer oral antibiotics with activity against Gram-positive organisms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For moderate and severe infections, offer antibiotics with activity against Gram-positive and Gram-negative organisms, including anaerobic bacteria. The route of administration is as follows:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Moderate infection: oral or intravenous antibiotics, based on the clinical situation and the choice of antibiotic (see recommendation above) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe infection: start with intravenous antibiotics then reassess, based on the clinical situation (see recommendation above) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The definitive antibiotic regimen and the duration of treatment should be informed by both the results of the microbiological examination and the clinical response to empiric antibiotic therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not use prolonged antibiotic therapy for mild soft tissue infections.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Treat infections with methicillin-resistant &lt;em&gt;Staphylococcus aureus&lt;/em&gt; (MRSA) in line with local and national guidance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Diabetic Foot Ulcers&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Debridement, Dressings and Off-Loading&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Debridement should only be done by healthcare professionals from the multidisciplinary foot care team, using the technique that best matches their specialist expertise, clinical experience, patient preference, and the site of the ulcer.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When choosing wound dressings, healthcare professionals from the multidisciplinary foot care team should take into account their clinical assessment of the wound, patient preference and the clinical circumstances, and should use wound dressings with the lowest acquisition cost.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Offer off-loading for patients with diabetic foot ulcers. Healthcare professionals from the multidisciplinary foot care team should take into account their clinical assessment of the wound, patient preference and the clinical circumstances, and should use the technique with the lowest acquisition cost.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Use pressure-relieving support surfaces and strategies in line with &lt;a href=&quot;http://guidance.nice.org.uk/CG29&quot; title=&quot;NICE Web site&quot;&gt;Pressure ulcers&lt;/a&gt; (NICE clinical guideline 29) to minimise the risk of pressure ulcers developing.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adjunctive Treatments&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Negative pressure wound therapy should not be routinely used to treat diabetic foot problems, but may be considered in the context of a clinical trial or as rescue therapy (when the only other option is amputation).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Do not offer the following treatments for the inpatient management of diabetic foot problems, unless as part of a clinical trial:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Dermal or skin substitutes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electrical stimulation therapy, autologous platelet-rich plasma gel, regenerative wound matrices and deltaparin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Growth factors (granulocyte colony-stimulating factor [G-CSF], platelet-derived growth factor [PDGF], epidermal growth factor [EGF] and transforming growth factor beta [TGF-&amp;beta;]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperbaric oxygen therapy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Assessment of Suspected Limb Ischaemia&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Limb ischaemia with redness and pain can be misdiagnosed as soft tissue infection. The new onset of gangrene of a digit or of the forefoot is often precipitated by soft tissue infection, even though the signs of inflammation may be attenuated by coincidental peripheral arterial disease.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;If limb ischaemia is suspected, obtain a history of any previous cardiovascular events and symptoms, including previous treatments and/or procedures. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inspect the limb for the following:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Colour and temperature &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Presence of gangrene or tissue loss &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Presence or absence of a peripheral pulse &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measure and document the ankle&amp;ndash;brachial pressure where clinically possible, ensuring careful interpretation of the results. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arrange prompt specialist assessment of patients with risk factors, symptoms and signs of limb ischaemia. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A care pathway for the multidisciplinary foot care team is provided in the full version of the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is not specifically stated for each recommendation.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate inpatient management of diabetic foot problems&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Treatment-related adverse effects, including complications of surgical debridement and wound dressings and adverse effects of antibiotic therapy&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This guidance represents the view of the National Institute for Health and Clinical Excellence (NICE), which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The National Institute for Health and Clinical Excellence (NICE) has developed tools to help organisations implement this guidance (see &lt;a href=&quot;http://guidance.nice.org.uk/CG119&quot; title=&quot;NICE Web site&quot;&gt;http://guidance.nice.org.uk/CG119&lt;/a&gt;; see also the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Key Priorities for Implementation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Multidisciplinary Foot Care Team&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Each hospital should have a care pathway for patients with diabetic foot problems who require inpatient care (the term 'diabetic foot problems requiring inpatient care' refers to people with diabetes who have i) an ulcer, blister or break in the skin of the foot; ii) inflammation or swelling of any part of the foot, or any sign of infection; iii) unexplained pain in the foot; iv) fracture or dislocation in the foot with no preceding history of significant trauma; v) gangrene of all or part of the foot. Diabetes UK [2009]: 'Putting feet first: commissioning specialist services for the management and prevention of diabetic foot disease in hospitals'.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The multidisciplinary foot care team should consist of healthcare professionals with the specialist skills and competencies necessary to deliver inpatient care for patients with diabetic foot problems. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The multidisciplinary foot care team should normally include a diabetologist, a surgeon with the relevant expertise in managing diabetic foot problems, a diabetes nurse specialist, a podiatrist and a tissue viability nurse, and the team should have access to other specialist services required to deliver the care outlined in this guideline. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The multidisciplinary foot care team should:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Assess and treat the patient's diabetes, which should include interventions to minimise the patient's risk of cardiovascular events, and any interventions for pre-existing chronic kidney disease or anaemia (please refer to &lt;a href=&quot;http://guidance.nice.org.uk/CG73&quot; title=&quot;NICE Web site&quot;&gt;Chronic kidney disease&lt;/a&gt; [NICE clinical guideline 73] and &lt;a href=&quot;/content.aspx?id=34281&quot; title=&quot;Guideline #8661&quot;&gt;Anaemia management in people with chronic kidney disease&lt;/a&gt; [NICE clinical guideline 114]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess, review and evaluate the patient's response to initial medical, surgical and diabetes management &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess the foot, and determine the need for specialist wound care, debridement, pressure off-loading and/or other surgical interventions &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess the patient's pain and determine the need for treatment and access to specialist pain services &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Perform a vascular assessment to determine the need for further interventions &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Review the treatment of any infection &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Determine the need for interventions to prevent the deterioration and development of Achilles tendon contractures and other foot deformities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Perform an orthotic assessment and treat to prevent recurrent disease of the foot &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Have access to physiotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Arrange discharge planning, which should include making arrangements for the patient to be assessed and their care managed in primary and/or community care, and followed up by specialist teams. Please refer to &lt;a href=&quot;http://guidance.nice.org.uk/CG10&quot; title=&quot;NICE Web site&quot;&gt;Type 2 diabetes: prevention and management of foot problems&lt;/a&gt; (NICE clinical guideline 10) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patient Information and Support&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The patient should have a named contact (this may be a member of the multidisciplinary foot care team or someone with a specific role as an inpatient pathway coordinator) to follow the inpatient care pathway and be responsible for:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Offering patients information about their diagnosis and treatment, and the care and support that they can expect &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Communicating relevant clinical information, including documentation prior to discharge, within and between hospitals and to primary and/or community care &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Examination and Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Remove the patient's shoes, socks, bandages and dressings and examine their feet for evidence of:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Neuropathy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ischaemia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ulceration &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Inflammation and/or infection &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Deformity &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Charcot arthropathy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Document any identified new and/or existing diabetic foot problems.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Obtain urgent advice from an appropriate specialist if any of the following are present:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Fever or any other signs or symptoms of systemic sepsis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Clinical concern that there is a deep-seated infection (for example palpable gas) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Limb ischaemia &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Care: Within 24 Hours of a Patient with Diabetic Foot Problems Being Admitted to Hospital, or the Detection of Diabetic Foot Problems (if the Patient Is Already in Hospital)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Refer the patient to the multidisciplinary foot care team within 24 hours of the initial examination of the patient's feet. Transfer the responsibility of care to a consultant member of the multidisciplinary foot care team if a diabetic foot problem is the dominant clinical factor for inpatient care. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Investigation of Suspected Diabetic Foot Infection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;If osteomyelitis is suspected and initial X-ray does not confirm the presence of osteomyelitis, use magnetic resonance imaging (MRI). If MRI is contraindicated, white blood cell (WBC) scanning may be performed instead. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Diabetic Foot Infection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Each hospital should have antibiotic guidelines for the management of diabetic foot infections. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Diabetic Foot Ulcers&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;When choosing wound dressings, healthcare professionals from the multidisciplinary foot care team should take into account their clinical assessment of the wound, patient preference and the clinical circumstances, and should use wound dressings with the lowest acquisition cost. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /><FieldValue Value="Slide Presentation" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Timeliness " /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Centre for Clinical Practice. Diabetic foot problems. Inpatient management of diabetic foot problems. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 31 p.&amp;nbsp;(Clinical guideline; no. 119).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011 Mar" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;National Institute for Health and Clinical Excellence&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline Development Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Development Group (GDG) Members&lt;/em&gt;: Peter Barry (GDG Chair), Consultant in Paediatric Intensive Care, University Hospitals of Leicester NHS Trust and Honorary Senior Lecturer, Department of Child Health, University of Leicester; Amanda Adler, Consultant Physician, Addenbrooke's Hospital; Anthony Berendt, Consultant Physician, Nuffield Orthopaedic Centre; Mark Collier, Nurse Consultant - Tissue Viability, United Lincolnshire Hospitals NHS Trust; Sunil Dhar, Consultant Orthopaedic Surgeon, University Hospitals of Nottingham; Nirupam Goenka, Consultant Physician, Countess of Chester NHS Foundation Trust; Katherine Hill, Patient member; Gerry Rayman, Consultant Physician, Ipswich Hospital NHS Trust; Clifford Shearman, Professor of Vascular Surgery/Consultant Vascular Surgeon, University of Southampton, Southampton General Hospital; Louise Stuart, Consultant Podiatrist, NHS Manchester; Gloria Travers, Patient member&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For the declarations of interests of all the contributors to this guideline, see Appendix N in the full version of the original guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies of the updated guideline: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.nice.org.uk/guidance/ng19&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Inpatient management of diabetic foot problems. Quick reference guide. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Jan. 8 p. (Clinical guideline; no. 119). Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/QuickRefGuide/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Inpatient management of diabetic foot problems. Full guideline. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 138 p. (Clinical guideline; no. 119). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/Guidance/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Inpatient management of diabetic foot problems. Appendices. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 436 p. (Clinical guideline; no. 119). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/Guidance/Appendices/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;NICE pathways. Diabetes. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011. Various pages. Available from the &lt;a href=&quot;http://pathways.nice.org.uk/pathways/diabetes#path=view%3A/pathways/diabetes/foot-care-for-people-with-diabetes.xml&amp;amp;content=close&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Inpatient management of diabetic foot problems. Costing statement. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 7 p. (Clinical guideline; no. 119). Electronic copies: Available in PDF from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/CostingStatement/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Audit support. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 14 p. (Clinical guideline; no. 119). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/AuditSupport/doc/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Inpatient management of diabetic foot problems. Baseline assessment tool. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 14 p. (Clinical guideline; no. 119). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/BaselineAssessment/xls/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Slide set. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 22 p. (Clinical guideline; no. 119). Electronic copies: Available from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/SlideSet/ppt/English&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems - inpatient management (in collaboration with Nursing Times). Online educational tool. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. Electronic copies: Available from the &lt;a href=&quot;http://www.nice.org.uk/usingguidance/education/educational_tools.jsp&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic foot problems. Podcast. Available from the &lt;a href=&quot;http://www.nice.org.uk/newsroom/podcasts/index.jsp?pid=17&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The guidelines manual 2009. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Jan. Electronic copies: Available from the &lt;a href=&quot;http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hospital-based treatment of diabetic foot problems. Understanding NICE guidance. Information for people who use NHS services. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Mar. 8 p. (Clinical guideline; no. 119). Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/PublicInfo/pdf/English&quot; title=&quot;NICE Web site&quot;&gt;National Institute for Health and Clinical Excellence (NICE) Web site&lt;/a&gt;. Also available in Welsh from the &lt;a href=&quot;http://guidance.nice.org.uk/CG119/PublicInfo/doc/Welsh&quot; title=&quot;NICE Web site&quot;&gt;NICE Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on March 22, 2012.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The National Institute for Health and Clinical Excellence (NICE) has granted the National Guideline Clearinghouse (NGC) permission to include summaries of their clinical guidelines with the intention of disseminating and facilitating the implementation of that guidance. NICE has not yet verified this content to confirm that it accurately reflects that original NICE guidance and therefore no guarantees are given by NICE in this regard. All NICE clinical guidelines are prepared in relation to the National Health Service in England and Wales. NICE has not been involved in the development or adaptation of NICE guidance for use in any other country. The full versions of all NICE guidance can be found at &lt;a href=&quot;http://www.nice.org.uk&quot; title=&quot;NICE Web site&quot;&gt;www.nice.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
